UBS Rates Oruka Therapeutics (ORKA) buy, $130 Price Target
UBS keeps its buy rating for Oruka Therapeutics, setting a $130 price target, a 36.60% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
UBS rated Oruka Therapeutics, Inc. ($ORKA) "buy" with a $130 price target on July 1, 2026.
Since the rating, $ORKA is down 9.5% after 1 week, up 3.5% after 1 month and down 22.9% to date (from the $93.29 close on Jul 1, 2026).
ORKA
Oruka Therapeutics, Inc.
Key Points
- UBS analyst Michael Yee reiterated a buy rating on Oruka Therapeutics with a $130 price target as of July 1, 2026.
- UBS's $130 price target implies 36.60% upside from Oruka Therapeutics, Inc.'s ($ORKA) current $95.17 share price.
- Shares of Oruka Therapeutics traded at $95.17 on Wednesday, with the company having a market cap of approximately $5.74 billion.
- Insider Joana Goncalves made both purchases and sales in June, while UBS and BTIG analysts continue to support a buy rating.
Get $ORKA trade alerts by text
We text you when insiders, Congress or big funds trade $ORKA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Oruka Therapeutics, Inc. alert may contain errors. Disclosures
On July 1, 2026, UBS analyst Michael Yee reiterated a buy rating on Oruka Therapeutics, Inc. (NasdaqGM: ORKA), setting a price target of $130. Shares traded at $95.17 on Wednesday. UBS's continued confidence in the stock suggests strong potential in Oruka's pipeline, focusing on novel treatments for psoriasis and other inflammatory conditions.
UBS vs. the S&P 500
Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Oruka Therapeutics
FMR LLC increased its holdings by 170,019 shares, resulting in a total of 7,431,403 shares valued at about $364.51 million, marking a 2.3% increase. Paradigm Biocapital Advisors LP also grew its stake significantly by 610,000 shares, a 35.7% increase, now holding 2,320,316 shares worth approximately $113.81 million. Meanwhile, BlackRock, Inc. slightly trimmed its position by 12,328 shares, leaving it with 3,527,087 shares valued at $173 million.
Oruka Therapeutics, Inc. Stock Up 28.8%
Shares of Oruka Therapeutics traded near $95.17 on Wednesday. The company has a market capitalization of approximately $5.74 billion. Oruka is not currently profitable, reflected in its forward P/E ratio of -38.65. The stock has shown significant volatility with a 52-week range between $10.97 and $97.78. The current ratios indicate strong liquidity, with a current ratio of 23.76 and a quick ratio of 23.38, while the debt-to-equity ratio stands at 0.37.
$ORKA price target
Oruka Therapeutics, Inc. daily closes and this analyst's $130 target. Not advice.
Insider Buying and Selling at Oruka Therapeutics, Inc.
In recent insider activity, Joana Goncalves, the Chief Medical Officer, purchased 7,000 shares at an average price of $7.32 on June 15, 2026. On the same day, Goncalves sold 3,500 shares without a specified price. Arjun Agarwal, Senior Vice President of Finance, sold 1,587 shares at an average price of $80.95 on June 22, 2026, as part of a planned transaction.
Analysts Set New Price Targets
On July 1, 2026, UBS maintained its buy rating on Oruka Therapeutics with a price target of $130. BTIG reiterated its buy rating on May 14, 2026, with a target of $151. The consensus among analysts is a strong buy, with a mean price target of $142.17 based on 12 analyst opinions.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. Led by CEO Dr. Lawrence Otto Klein, the company focuses on developing monoclonal antibody therapeutics targeting psoriasis and other inflammatory and immunological conditions. Their leading projects include ORKA-001 and ORKA-002, which are in phase 2 trials for treating psoriasis and psoriatic arthritis.
Bottom Line
UBS's reiteration of a buy rating and a $130 price target underscores confidence in Oruka Therapeutics' potential, despite its current lack of profitability. With a robust pipeline and ongoing clinical trials, the company is a significant player in the biotechnology sector. Investors should note that analyst ratings and insider activities provide insights but reflect past decisions.
Related Filing Alerts
Source: UBS's rating change on $ORKA (Jul 1, 2026). Written by software, not financial advice. How we make alerts